Anticancer Prodrug Capable of Mitochondria-Targeting, Light-Triggered Release, and Fluorescence Monitoring.
ACS Appl Bio Mater
; 7(6): 3991-3996, 2024 Jun 17.
Article
en En
| MEDLINE
| ID: mdl-38835291
ABSTRACT
Mitigating the adverse effects of anticancer agents requires innovative prodrug engineering. In this study, we showcase the potential of our o-quinone methide-based trigger-release-conjugation platform as a versatile tool for constructing advanced prodrug systems. Using this platform, we achieved the light-triggered release of an anticancer drug mechlorethamine, targeting mitochondrial DNA. The entire process was adeptly tracked through the emission of fluorescence signals, revealing notable effects across various cancer cell lines compared to a normal cell line. Exploring alternative cancer-associated triggers, including enzymes, and incorporating cancer/tumor-specific targeting elements could lead to effective prodrugs with reduced cytotoxicity.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ensayos de Selección de Medicamentos Antitumorales
/
Profármacos
/
Luz
/
Mitocondrias
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
ACS Appl Bio Mater
Año:
2024
Tipo del documento:
Article
País de afiliación:
Corea del Sur